XML 27 R14.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS’ EQUITY
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 8 – STOCKHOLDERS’ EQUITY

 

The Company has authorized the issuance of up to 100,000,000 shares of common stock, $0.01 par value, and 5,000,000 shares of preferred stock, $0.0001 par value, of which 5,000 shares are designated as Series B Preferred Stock, 1,610,000 are designated as Series A Preferred Stock and 3,385,000 shares of preferred stock remain undesignated.

 

On June 8, 2021, the Company filed the 2021 Shelf. Under the 2021 Shelf at the time of effectiveness, the Company originally had the ability to raise up to $150 million by selling common stock, preferred stock, debt securities, warrants and units. In conjunction with the 2021 Shelf, the Company also entered into the ATM Sales Agreement whereby the Company may offer and sell, from time to time, shares of common stock. On March 22, 2023, the date the Company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, the Company became subject to the offering limits in General Instruction I.B.6 of Form S-3 (i.e., the “baby shelf limitations”). As a result of the baby shelf limitations, the Company may only offer and sell shares of common stock having an aggregate offering price of up to $18.435 million pursuant to the ATM Sales Agreement, and it filed a prospectus supplement with the SEC to that effect on March 27, 2023. In June 2023, the Company’s public float increased above $75.0 million. As a result, the Company is no longer subject to the baby shelf limitations. The Company filed another prospectus supplement with the SEC to that effect on June 29, 2023. As of September 30, 2023, the Company has $58.6 million available under the ATM Sales Agreement.

 

Options

 

During the nine months ended September 30, 2023, the Company issued an aggregate of 74,372 shares of common stock related to the cashless exercise of options.

 

Common Stock

 

Common Stock Transactions During the Nine Months Ended September 30, 2023

 

During the nine months ended September 30, 2023, the Company issued an aggregate of 339,875 shares of common stock for service, including vested restricted stock units.

 

On February 4, 2023, the Company entered into the First Amendment to the Stock Purchase Agreement (the “First Amendment”) between the Company and the sellers of Cleared. The First Amendment was amended to, among other things change the timing of the payment of the purchase price to $460 thousand paid at closing (which has already been paid by the Company), with the remaining amount to be paid in five quarterly installments beginning on or before February 6, 2023 and ending January 15, 2024. On February 6, 2023, the Company issued 337,895 shares of common stock related to the first of five quarterly installment payments due to the sellers of Cleared under the First Amendment. On April 17, 2023, the Company issued 455,319 shares of common stock related to the second of five quarterly installment payments due to the sellers of Cleared under the First Amendment. On July 17, 2023, the Company issued 158,129 shares of common stock related to the third of five quarterly installment payments due to the sellers of Cleared under the First Amendment.

 

During the nine months ended September 30, 2023, the Company sold 180,021 shares of common stock under the ATM Sales Agreement and net proceeds received were $900 thousand.

 

During the nine months ended September 30, 2023, the Company issued 100,000 shares of common stock related to the settlement of the Harborside Advisors LLC v. LifeMD, Inc., Case No. 21-cv-10593, and the Specialty Medical Drugstore, LLC D/B/A GoGoMeds v. LifeMD, Inc., Case No. 21-cv-10599, matters. The shares issued were valued based on the closing price of the Company’s stock, or $5.32, on the date of settlement, July 10, 2023.

 

 

On July 10, 2023, and August 14, 2023, PA001 Holdings, LLC, the holder of the Company’s Series B Preferred Stock, elected to convert 2,275 and 1,225 shares, respectively, of the Company’s Series B Preferred Stock, at a price of $3.25 per share of Series B Preferred Stock, pursuant to the terms of the Securities Purchase Agreement dated August 28, 2020. The conversion was calculated based on the original issuance price of the Series B Preferred Stock plus all accrued dividends to date. The conversion resulted in 1,010,170 and 550,694 shares of the Company’s common stock issued to PA001 Holdings, on July 12, 2023 and August 15, 2023, respectively.

 

On March 21, 2023, in connection with the Company’s closing of a Credit Agreement with Avenue, the Company issued Avenue warrants to purchase $1.2 million of the Company’s common stock at an exercise price of $1.24, subject to adjustments. In addition, Avenue may convert up to $2 million of the $15 million in term loans funded at closing into shares of the Company’s common stock at any time while the loans are outstanding, at a price per share equal to $1.49.

 

Noncontrolling Interest

 

Net income attributed to the non-controlling interest amounted to $839 thousand and $84 thousand for the three months ended September 30, 2023 and 2022, respectively. During both the three months ended September 30, 2023 and 2022, the Company paid distributions to non-controlling shareholders of $36 thousand. Net income attributed to the non-controlling interest amounted to $2.2 million and $155 thousand for the nine months ended September 30, 2023 and 2022, respectively. During both the nine months ended September 30, 2023 and 2022, the Company paid distributions to non-controlling shareholders of $108 thousand.

 

WorkSimpli Software Restructuring Transaction

 

Effective January 22, 2021 (the “WSS Effective Date”), the Company consummated the WSS Restructuring, which is described in Note 1. To effect the WSS Restructuring the Company’s wholly-owned subsidiary Conversion Labs PR, entered into a series of membership interest exchange agreements, pursuant to which, Conversion Labs PR exchanged that certain promissory note, dated May 8, 2019 with an outstanding balance of $376 thousand (the “CVLBPR Note”), issued by WSS in favor of Conversion Labs PR, for 37,531 newly issued membership interests of WSS (the “Exchange”). Upon consummation of the Exchange the CVLBPR Note was extinguished.

 

Concurrently, in furtherance of the WSS Restructuring, Conversion Labs PR entered into two Membership Interest Purchase Agreements (the “Founding Members MIPAs”) with two founding members of WSS (the “Founding Members”) whereby Conversion Labs PR purchased from the Founding Members an aggregate of 2,183 membership interests of WSS for an aggregate purchase price of $225,000, paid in December 2020.

 

In furtherance of the WSS Restructuring, Conversion Labs PR entered into a Membership Interest Purchase Agreement with WSS, (the “CVLB PR MIPA”), pursuant to which Conversion Labs PR purchased 12,000 membership interests of WSS for an aggregate purchase price of $300 thousand. The CVLB PR MIPA provides that the transaction may be completed in three (3) tranches with a purchase price of $100 thousand per tranche to be made at the sole discretion of Conversion Labs PR. Payment for the first tranche of $100 thousand was made upon execution of the CVLB PR MIPA in January 2021. Payments for the second and third tranches were made on the 60-day anniversary and the 120-day anniversary of the WSS Effective Date.

 

Following the consummation of the WSS Restructuring, Conversion Labs PR increased its ownership of WSS from 51% to approximately 85.58% on a fully diluted basis. WSS entered into an amendment to its operating agreement (the “WSS Operating Agreement Amendment”) to reflect the change in ownership.

 

Concurrently with the WSS Restructuring, Conversion Labs PR entered into option agreements with Sean Fitzpatrick (the “Fitzpatrick Option Agreement”) and Varun Pathak (the “Pathak Option Agreement” together with Fitzpatrick Option Agreement the “Option Agreements”), pursuant to which Conversion Labs PR granted options to purchase membership interest units of WSS. Upon vesting, the Fitzpatrick Options and the Pathak Options provide for the potential re-purchase of up to an additional 13.25% of WSS by Fitzpatrick and Pathak in the aggregate with Conversion Labs PR ownership ratably reduced to approximately 72.98%.

 

The Fitzpatrick Option Agreement grants Sean Fitzpatrick the option to purchase 10,300 membership interest units of WSS for an exercise price of $1.00 per membership interest unit. The Fitzpatrick Options vest in accordance with the following milestones (i) 3,434 membership interests upon WSS achieving $2.5 million of gross sales in any fiscal quarter (ii) 3,434 membership interests upon WSS achieving $4.0 million of gross sales in any fiscal quarter, and (iii) 3,434 membership interests upon WSS achieving $8.0 million of gross sales with a ten percent (10%) net profit margin in any fiscal quarter.

 

The Pathak Option Agreement grants Varun Pathak the option to purchase 2,100 membership interest units of WSS for an exercise price of $1.00 per membership interest unit. The Pathak Options vest in accordance with the following milestones (i) 700 membership interests upon WSS achieving $2.5 million of gross sales in any fiscal quarter (ii) 700 membership interests upon WSS achieving $4.0 million of gross sales in any fiscal quarter, and (iii) 700 membership interests upon WSS achieving $8.0 million of gross sales with a ten percent (10%) net profit margin in any fiscal quarter.

 

 

On September 30, 2022, Sean Fitzpatrick and Varun Pathak exercised their options to purchase 10,300 and 2,100 membership interest units, respectively, of WorkSimpli for an exercise price of $1.00 per membership interest unit under the Option Agreements. Following the exercise of the Option Agreements, Conversion Labs PR decreased its ownership interest in WorkSimpli from 85.58% to 73.64%. Effective March 31, 2023, the Company redeemed 500 membership interest units in WorkSimpli. Following the retirement, Conversion Labs PR’s ownership interest in WorkSimpli increased to 74.06%. On June 30, 2023, Lisa Bowlin, WorkSimpli’s Chief Operating Officer, exercised her option agreement (the “Bowlin Option Agreement”) to purchase 889 membership interest units of WorkSimpli for an exercise price of $1.00 per membership interest unit. Following the exercise of the Bowlin Option Agreement, Conversion Labs PR decreased its ownership interest in WorkSimpli from 74.06% to 73.32%.

 

On June 30, 2023, WorkSimpli declared a cash dividend in the amount of $22.40 per membership interest unit to all unit holders of record as of June 30, 2023 and was paid on July 3, 2023. On July 31, 2023, WorkSimpli declared a cash dividend in the amount of $11.20 per membership interest unit to all unit holders of record as of July 28, 2023 and was paid on August 1, 2023. On August 31, 2023, WorkSimpli declared a cash dividend in the amount of $16.80 per membership interest unit to all unit holders of record as of August 30, 2023 and was paid on September 1, 2023. On September 30, 2023, WorkSimpli declared a cash dividend in the amount of $14.00 per membership interest unit to all unit holders of record as of September 30, 2023 and was paid on October 5, 2023. The total dividends declared to noncontrolling interest holders was $1.0 million and $1.5 million for the three and nine months ended September 30, 2023, respectively, and is included in the Company’s results of operations for the three and nine months ended September 30, 2023.

 

Dividends

 

The Company pays cumulative dividends on its Series A Preferred Stock, in the amount of $2.21875 per share each year, which is equivalent to 8.875% of the $25.00 liquidation preference per share. Dividends on the Series A Preferred Stock are payable quarterly in arrears, on or about the 15th day of January, April, July, and October of each year. Dividends declared and paid on the Series A Preferred Stock during the nine months ended September 30, 2023 are as follows: (1) quarterly dividend declared on March 28, 2023 to holders of record as of April 7, 2023 and was paid on April 17, 2023, (2) quarterly dividend declared on June 27, 2023 to holders of record as of July 7, 2023 and was paid on July 17, 2023 and (3) quarterly dividend declared on September 26, 2023 to holders of record as of October 6, 2023 and was paid on October 16, 2023. The dividends are included in the Company’s results of operations for the three and nine months ended September 30, 2023.

 

Stock Options

 

On January 8, 2021, the Company approved the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”). Approval of the 2020 Plan was included as Proposal 1 in the Company’s definitive proxy statement for its Special Meeting of Shareholders filed with the Securities and Exchange Commission on December 7, 2020. The 2020 Plan is administered by the Compensation Committee of the Board of Directors (the “Board”) and initially provided for the issuance of up to 1,500,000 shares of Common Stock. The number of shares of Common Stock available for issuance under the 2020 Plan automatically increases by 150,000 shares of Common Stock on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030. Awards under the 2020 Plan can be granted in the form of stock options, non-qualified and incentive options, stock appreciation rights, restricted stock, and restricted stock units.

 

On June 24, 2021, at the Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares.

 

On June 16, 2022, at the Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares. As of September 30, 2023, the 2020 Plan, as amended, provided for the issuance of up to 4,950,000 shares of Common Stock. Remaining authorization under the 2020 Plan, as amended, was 441,611 shares as of September 30, 2023.

 

The forms of award agreements to be used in connection with awards made under the 2020 Plan to the Company’s executive officers and non-employee directors are:

 

● Form of Non-Qualified Option Agreement (Non-Employee Director Awards)
● Form of Non-Qualified Option Agreement (Employee Awards); and
● Form of Restricted Stock Award Agreement.

 

Previously, the Company had granted service-based stock options and performance-based stock options separate from the 2020 Plan.

 

 

During the nine months ended September 30, 2023, the Company issued an aggregate of 234,500 stock options to employees under the 2020 Plan and the prior plan. These stock options have a contractual term of 4 to 6.5 years and vest in increments which fully vest the options over a two to three-year period, dependent on the specific agreements’ terms.

 

The following is a summary of outstanding options activity under our 2020 Plan for the nine months ended September 30, 2023:

 

  

Options

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

 

Weighted

Average

Exercise Price

per Share

 
                
Balance, December 31, 2022   1,784,587   $2.30 – 21.02   6.95 years  $9.54 
Granted   94,500    1.84 – 7.44   4.27 years   3.30 
Cancelled/Forfeited/Expired   (1,006,698)   2.30 – 21.02       10.01 
Balance at September 30, 2023   872,389   $1.84 – 13.74   5.34 years  $8.32 
                   
Exercisable at December 31, 2022   1,185,153   $2.30 – 21.02   7.64 years  $9.62 
Exercisable at September 30, 2023   677,625   $1.84 – 13.74   6.42 years  $8.58 

 

The total fair value of the options granted was $265 thousand, which was determined by the Black-Scholes Pricing Model with the following assumptions: dividend yield of 0%, expected term of 4 years, volatility of 119.16% – 133.67% and risk-free rate of 0.82% – 3.96%. Total compensation expense under the 2020 Plan options above was $1.2 million and $1.4 million for the three months ended September 30, 2023 and 2022, respectively, with unamortized expense remaining of $2.1 million as of September 30, 2023. Total compensation expense under the 2020 Plan options above was $3.5 million and $4.9 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, aggregate intrinsic value of vested service-based options outstanding was $550 thousand.

 

The following is a summary of outstanding service-based options activity (prior to the establishment of our 2020 Plan above) for the nine months ended September 30, 2023:

 

  

Options

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

 

Weighted

Average

Exercise Price

per Share

 
                
Balance, December 31, 2022   1,439,333   $1.00 – 19.61   5.63 years  $6.11 
Granted   140,000    1.00 – 2.00   2.19 years   1.71 
Exercised   (120,000)   1.00 – 1.50   4.59 years   1.33 
Cancelled/Forfeited/Expired   (200,000)   14.04       14.04 
Balance at September 30, 2023   1,259,333   $1.00 – 19.61   4.96 years  $4.82 
                   
Exercisable December 31, 2022   1,158,764   $1.00 – 19.61   5.63 years  $5.25 
Exercisable at September 30, 2023   1,198,208   $1.00 – 19.61   4.94 years  $4.65 

 

The total fair value of the options granted was $142 thousand, which was determined by the Black-Scholes Pricing Model with the following assumptions: dividend yield of 0%, expected term of 6.5 years, volatility of 187.76% – 195.58% and risk-free rate of 1.21% – 2.26%. Total compensation expense under the above service-based option plan was $367 thousand and $493 thousand for the three months ended September 30, 2023 and 2022, respectively, with unamortized expense remaining of $525 thousand as of September 30, 2023. Total compensation expense under the above service-based option plan was $1.5 million and $1.6 million for the nine months ended September 30, 2023 and 2022, respectively. Of the total service-based options exercised during the nine months ended September 30, 2023, 120,000 options were exercised on a cashless basis, which resulted in 74,372 shares issued. As of September 30, 2023, aggregate intrinsic value of vested service-based options outstanding was $3.3 million.

 

 

The following is a summary of outstanding performance-based options activity (separate from the 2020 Plan) for the nine months ended September 30, 2023:

 

  

Options

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

 

Weighted

Average

Exercise Price

per Share

 
                
Balance at December 31, 2022   535,000   $1.25 – 2.50   4.59 years  $1.60 
Cancelled/Forfeited/Expired   (50,000)   2.00       2.00 
Balance at September 30, 2023   485,000   $1.25 – 2.50   4.38 years  $1.56 
                   
Exercisable December 31, 2022   470,000   $1.50 – 2.50   4.58 years  $1.61 
Exercisable at September 30, 2023   420,000   $1.50 – 2.50   4.45 years  $1.56 

 

No compensation expense was recognized on the performance-based options above for the three and nine months ended September 30, 2023, as the performance terms have not been met or are not probable. Total compensation expense under the above performance-based options was $106 thousand and $317 thousand for the three and nine months ended September 30, 2022, respectively. As of September 30, 2023, aggregate intrinsic value of vested performance options outstanding was $2.0 million.

 

RSUs and RSAs

 

The following is a summary of outstanding RSUs and RSAs activity under our 2020 Plan for the nine months ended September 30, 2023:

 

  

RSU Outstanding

Number of Shares

 
Balance at December 31, 2022   1,028,250 
Granted   3,082,750 
Vested   (474,625)
Cancelled/Forfeited   (730,000)
Balance at September 30, 2023   2,906,375 

 

The total fair value of the 3,082,750 RSUs and RSAs granted was $10.5 million which was determined using the fair value of the quoted market price on the date of grant. Total compensation expense under the 2020 Plan RSUs and RSAs above was $1.6 million and $703 thousand for the three months ended September 30, 2023 and 2022, respectively, with unamortized expense remaining of $5.7 million as of September 30, 2023. Total compensation expense under the 2020 Plan RSUs and RSAs above was $3.1 million and $2.3 million for the nine months ended September 30, 2023 and 2022, respectively. During the nine months ended September 30, 2023, 474,625 RSUs and RSAs vested, of which 139,875 RSUs and RSAs were issued. During the nine months ended September 30, 2023, 655,000 RSUs and 809,000 service-based stock options were cancelled and replaced with 1,830,750 RSAs for four executives and two employees. Incremental compensation cost resulting from the modifications was immaterial to the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023.

 

The following is a summary of outstanding RSUs and RSAs activity (outside of our 2020 Plan) for the nine months ended September 30, 2023:

 

  

RSU Outstanding

Number of Shares

 
Balance at December 31, 2022   715,000 
Granted   725,000 
Vested   (327,500)
Cancelled/Forfeited   (500,000)
Balance at September 30, 2023   612,500 

 

The total fair value of the 725,000 RSUs and RSAs granted was $2.0 million which was determined using the fair value of the quoted market price on the date of grant. Total compensation expense for RSUs and RSAs outside of the 2020 Plan was $139 thousand and $225 thousand for the three months ended September 30, 2023 and 2022, respectively, with unamortized expense remaining of $1.3 million as of September 30, 2023. Total compensation expense for RSUs and RSAs outside of the 2020 Plan was $728 thousand and $1.2 million for the nine months ended September 30, 2023 and 2022, respectively. During the nine months ended September 30, 2023, 327,500 RSUs and RSAs vested, of which 200,000 RSUs and RSAs were issued. During the nine months ended September 30, 2023, 300,000 RSUs were cancelled and replaced with 300,000 RSAs for one executive. Incremental compensation cost resulting from the modification was immaterial to the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023.

 

 

Warrants

 

The following is a summary of outstanding and exercisable warrants activity during the nine months ended September 30, 2023:

 

  

Warrants

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

  

Weighted

Average

Exercise Price

per Share

 
Balance at December 31, 2022   3,859,638    $1.40 – 12.00    5.85 years   $5.59 
Granted   967,742    1.24    4.47 years    1.24 
Balance at September 30, 2023   4,827,380    $1.24 – 12.00    4.21 years   $4.74 
                     
Exercisable December 31, 2022   3,836,993    $1.40 – 12.00    4.88 years   $5.63 
Exercisable September 30, 2023   4,827,380    $1.24 – 12.00    4.21 years   $4.73 

 

The total fair value of the warrants granted during the nine months ended September 30, 2023, was $895 thousand, which was determined by the Black-Scholes Pricing Model with the following assumptions: dividend yield of 0%, expected term of 4 years, volatility of 122.6% and risk-free rate of 3.73%. No stock-based compensation expense on the warrants granted during the nine months ended September 30, 2023 was recorded as the warrants are amortized through debt discount (see Note 7).

 

Total compensation expense for warrants granted prior to the nine months ended September 30, 2023 was $0 and $407 thousand for the three months ended September 30, 2023 and 2022, respectively, with no unamortized expense remaining as of September 30, 2023. Total compensation expense for warrants granted prior to the nine months ended September 30, 2023 was $18 thousand and $1.6 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, aggregate intrinsic value of vested warrants outstanding was $10.2 million.

 

Stock-based Compensation

 

The total stock-based compensation expense related to common stock issued for services, service-based stock options, performance-based stock options, warrants, RSUs and RSAs amounted to $3.3 million for both the three months ended September 30, 2023 and 2022. The total stock-based compensation expense related to common stock issued for services, service-based stock options, performance-based stock options, warrants RSUs and RSAs amounted to $8.8 million and $11.9 million for the nine months ended September 30, 2023 and 2022, respectively. Such amounts are included in general and administrative expenses in the unaudited condensed consolidated statement of operations. Unamortized expense remaining related to service-based stock options, performance-based stock options, warrants, RSUs and RSAs was $9.6 million as of September 30, 2023, which is expected to be recognized through 2026.